Treatment

After extensive discussions of limited burosumab safety data during pregnancy, the potential for transplacental drug transfer, and the uncertain fetal effects depending on the inheritance of the PHEX variant, a shared decision was made to continue burosumab at the same dose (50 mg every 4 weeks) throughout pregnancy with close maternal and fetal monitoring; conventional therapy was not reintroduced.